StreetInsider.com News Articles

Form 144 INSMED Inc Filed by: Lewis William

Thu, 05 Mar 2026 17:00:00 -0500

si-local-file:///var/storage/secattach/20260305/26120086.html

Form 144 INSMED Inc Filed by: Lewis William

Thu, 05 Mar 2026 17:00:00 -0500

si-local-file:///var/storage/secattach/20260305/26120086.html

Form 4 INSMED Inc For: Mar 05 Filed by: Lewis William

Thu, 05 Mar 2026 16:17:00 -0500

si-local-file:///var/storage/secattach/20260305/26119201.html

Form 4 INSMED Inc For: Mar 05 Filed by: Lewis William

Thu, 05 Mar 2026 16:17:00 -0500

si-local-file:///var/storage/secattach/20260305/26119201.html

Form 4 INSMED Inc For: Mar 03 Filed by: SHAROKY MELVIN MD

Thu, 05 Mar 2026 16:15:00 -0500

si-local-file:///var/storage/secattach/20260305/26119140.html

Form 4 INSMED Inc For: Mar 03 Filed by: SHAROKY MELVIN MD

Thu, 05 Mar 2026 16:15:00 -0500

si-local-file:///var/storage/secattach/20260305/26119140.html

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Thu, 05 Mar 2026 07:00:00 -0500

BRIDGEWATER, N.J., March 5, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 85 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Thu, 05 Mar 2026 07:00:00 -0500

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Thu, 05 Mar 2026 07:00:00 -0500

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Thu, 05 Mar 2026 07:00:00 -0500

Form 4 INSMED Inc For: Feb 25 Filed by: SHAROKY MELVIN MD

Fri, 27 Feb 2026 16:19:00 -0500

si-local-file:///var/storage/secattach/20260227/26081953.html

Form 4 INSMED Inc For: Feb 25 Filed by: SHAROKY MELVIN MD

Fri, 27 Feb 2026 16:19:00 -0500

si-local-file:///var/storage/secattach/20260227/26081953.html

Buy this pharma stock at current levels, Mizuho

Thu, 26 Feb 2026 16:00:00 -0500

Shares of one pharmaceutical company dropped more than 6% on Wednesday amid concerns over a potential competitive threat, but analysts at Mizuho say the selloff is overdone and presents a buying opportunity.

In a note to clients, the firm wrote: “We believe the magnitude of Insmed's (NASDAQ: INSM) slide yesterday was unwarranted… we recommend aggressively buying INSM.”

The decline followed comments from United Therapeutics about a new soft mist inhaler device, Tresmi, being developed for its Tyvaso franchise.

Tresmi is described by United Therapeutics as a potential “category killer product,” designed to cut coughing by up to 90% compared with current

Buy this pharma stock at current levels, Mizuho

Thu, 26 Feb 2026 16:00:00 -0500

In a note to clients, the firm wrote: “We believe the magnitude of Insmed's (NASDAQ: INSM) slide yesterday was unwarranted… we recommend aggressively buying INSM.”

The decline followed comments from United Therapeutics about a new soft mist inhaler device, Tresmi, being developed for its Tyvaso franchise.

Tresmi is described by United Therapeutics as a potential “category killer product,” designed to cut coughing by up to 90% compared with current

Form 4 INSMED Inc For: Feb 24 Filed by: Smith Michael Alexander

Wed, 25 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260225/26059690.html

Form 4 INSMED Inc For: Feb 24 Filed by: Smith Michael Alexander

Wed, 25 Feb 2026 16:05:00 -0500

si-local-file:///var/storage/secattach/20260225/26059690.html

Form 4 INSMED Inc For: Feb 23 Filed by: Brennan David R

Wed, 25 Feb 2026 16:04:00 -0500

si-local-file:///var/storage/secattach/20260225/26059609.html

Form 4 INSMED Inc For: Feb 23 Filed by: Brennan David R

Wed, 25 Feb 2026 16:04:00 -0500

si-local-file:///var/storage/secattach/20260225/26059609.html

Form 144 INSMED Inc Filed by: Smith Michael Alexander

Tue, 24 Feb 2026 16:33:00 -0500

si-local-file:///var/storage/secattach/20260224/26052289.html

Form 144 INSMED Inc Filed by: Smith Michael Alexander

Tue, 24 Feb 2026 16:33:00 -0500

si-local-file:///var/storage/secattach/20260224/26052289.html

Form 4 INSMED Inc For: Feb 19 Filed by: Lewis William

Mon, 23 Feb 2026 16:34:00 -0500

si-local-file:///var/storage/secattach/20260223/26043993.html

Form 4 INSMED Inc For: Feb 19 Filed by: Lewis William

Mon, 23 Feb 2026 16:34:00 -0500

si-local-file:///var/storage/secattach/20260223/26043993.html

H.C. Wainwright Reiterates Buy Rating on Insmed (INSM)

Mon, 23 Feb 2026 06:37:20 -0500

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $230.00 price target on Insmed (NASDAQ: INSM).

The analyst commented: "We believe that Insmed providing 2026 revenue guidance for Brinsupri of +$1B earlier than expected is a positive indication for both improved clarity into the payer/market access landscape and early launch metrics tracking at/above internal targets. At this time, INSM has not increased peak Brinsupri revenue, which is still expected to be $5B+. We currently model ~$5B Brinsupri peak revenue for bronchiectasis, and will await further clarification on INSM's efforts to expand into COPD and asthma, which could represent potentially upwards

Insmed (INSM) PT Raised to $166 at Morgan Stanley

Fri, 20 Feb 2026 08:45:31 -0500

Morgan Stanley analyst Maxwell Skor raised the price target on Insmed (NASDAQ: INSM) to $166.00 (from $162.00) while maintaining a Equalweight rating.

Insmed (INSM) PT Lowered to $208 at Wells Fargo

Fri, 20 Feb 2026 07:09:20 -0500

Wells Fargo analyst Ben Burnett lowered the price target on Insmed (NASDAQ: INSM) to $208.00 (from $234.00) while maintaining a Overweight rating.